• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.

作者信息

Kurita Noriaki, Ito Takako, Shimizu Sayaka, Hirata Takumi, Uchihara Hirotsugu

机构信息

Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan Department of Medicine, Mikamikai Yasu Hospital, Shiga, Japan Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

Department of Nursing, Mikamikai Yasu Hospital, Shiga, Japan.

出版信息

Diabetes Care. 2014 Sep;37(9):e198-9. doi: 10.2337/dc14-1252.

DOI:10.2337/dc14-1252
PMID:25147262
Abstract
摘要

相似文献

1
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.维格列汀诱发的特异质性肝损伤，一名接受血液透析的糖尿病患者成功换用利格列汀
Diabetes Care. 2014 Sep;37(9):e198-9. doi: 10.2337/dc14-1252.
2
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.一项从 II 期和 III 期临床试验大型综合数据库中评估维格列汀与对照药物在肝脏、胰腺、免疫系统、皮肤以及肾功能受损患者中不良反应的研究。
Diabetes Obes Metab. 2010 Jun;12(6):495-509. doi: 10.1111/j.1463-1326.2010.01214.x.
3
[Therapeutic use and adverse events of incretin-related drugs].[肠促胰岛素相关药物的治疗用途及不良事件]
Nihon Rinsho. 2012 May;70 Suppl 3:699-702.
4
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.维格列汀单药治疗。与其他二肽基肽酶-4抑制剂一样，应避免使用。
Prescrire Int. 2013 May;22(138):121.
5
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.三例与二肽基肽酶-4抑制剂相关的大疱性类天疱疮——其中一例由利格列汀引起。
Dermatology. 2016;232(2):249-53. doi: 10.1159/000443330. Epub 2016 Jan 28.
6
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.用于透析患者的非胰岛素类降糖药。
Nat Rev Nephrol. 2013 Mar;9(3):147-53. doi: 10.1038/nrneph.2013.12. Epub 2013 Jan 29.
7
A case of bullous pemphigoid ınduced by vildagliptin.一例由维格列汀诱发的大疱性类天疱疮。
Cutan Ocul Toxicol. 2017 Jun;36(2):201-202. doi: 10.1080/15569527.2016.1211670. Epub 2016 Aug 11.
8
Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.临床实践中的注意事项和文献回顾：DPP-4 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的应用。
Endocr Pract. 2013 Nov-Dec;19(6):1025-34. doi: 10.4158/EP12306.RA.
9
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].二肽基肽酶-4抑制剂（格列汀类）：一类新型口服抗糖尿病药物
Orv Hetil. 2011 Sep 11;152(37):1471-6. doi: 10.1556/OH.2011.29207.
10
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?二肽基肽酶-4 抑制剂与血管性水肿：类效应？
Diabet Med. 2013 Apr;30(4):e149-50. doi: 10.1111/dme.12134.

引用本文的文献

1
Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.2型糖尿病患者中基于肠促胰岛素的治疗与肝胆疾病的关联：来自美国食品药品监督管理局不良事件报告系统的病例系列
Endocr Connect. 2024 Nov 25;13(12). doi: 10.1530/EC-24-0404. Print 2024 Dec 1.
2
Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control.机器学习评估维格列汀和利拉利汀在 2 型糖尿病中的疗效：血糖控制的预测因素。
PLoS One. 2024 Aug 26;19(8):e0309365. doi: 10.1371/journal.pone.0309365. eCollection 2024.
3
Evaluation of the Drug-Induced Liver Injury Potential of Saxagliptin through Reactive Metabolite Identification in Rats.
通过在大鼠中鉴定反应性代谢物评估沙格列汀的药物性肝损伤潜力
Pharmaceutics. 2024 Jan 13;16(1):106. doi: 10.3390/pharmaceutics16010106.
4
Acute Liver Injury Induced by Sitagliptin: Report of Two Cases and Review of Literature.西他列汀所致急性肝损伤：2例报告及文献复习
Cureus. 2018 Jun 11;10(6):e2776. doi: 10.7759/cureus.2776.
5
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies.CMD-05，一种新型有前景的临床抗糖尿病药物候选物，体内和体外研究。
Sci Rep. 2017 Apr 13;7:46628. doi: 10.1038/srep46628.
6
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.维格列汀及其代谢物M20.7可诱导人肝癌HepG2细胞和白血病HL-60细胞中S100A8和S100A9的表达。
Sci Rep. 2016 Oct 19;6:35633. doi: 10.1038/srep35633.